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Neuropathological changes such as dystrophic neurites and the presence of
abnormal Ù protein in the olfactory system, including primary sensory cells
and nerve fibres have previously been demonstrated in nasal mucosa tissue of
patients with Alzheimer’s disease (AD). These changes were detected in autop-
sy-derived material from histopathologically confirmed AD cases as well as in
biopsy tissue from clinical severely ill AD patients. To investigate the poten-
tial usefulness for the early diagnosis of AD, we obtained biopsy tissue from
olfactory mucosa from 5 clinically mild to moderate AD patients and stained
for the presence of Ù or ß-amyloid by immunocytochemistry using a panel of
specific antibodies. No positive staining was found in any of the cases. For
comparison, post-mortem olfactory tissue from AD patients with severe neu-
ropathological changes (widespread neurofibrillary tangles and amyloid in the
brain) was investigated. In these severe cases, Ù immunoreactivity was found
in fine nerve fibres in the lamina propria and in a few olfactory epithelial cells.
These results are consistent with other reports showing that cytoskeletal
changes and Ù pathology in the olfactory epithelium are not primary (or spe-
cific) features of AD and may occur predominantly in late stages of the dis-
ease.
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Alzheimer’s disease (AD) is a common neurodegenera-
tive disorder that leads to dementia and death. Consistent
pathological hallmarks of AD are the formation of brain
amyloid, consisting mainly of amyloid ß-peptides (Aß),
and neurofibrillary tangles (NFTs, and their constituent
paired helical filaments), with the microtubule-associated
protein Ù as the major component [for a review, see 1].
The clinical manifestation of the disease may be preceded
by cerebral amyloid deposition for years, if not decades
[2, 3]. Therefore, neurodegeneration in AD is regarded as
a long-term process that may be eliminated only by pre-
ventive therapeutic strategies. The availability of valid
markers for early diagnosis is a major prerequisite for
establishing preventive or therapeutic strategies in AD.
Several studies have suggested that olfactory deficiencies
may be one of the early signs of neurodegeneration in AD
[4]. Because human olfactory mucosa contains neuronal
structures of ontogenetic central origin, it is suspected
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that signs of neurodegeneration might be detected in this
area in early clinical or even preclinical stages of AD. Tal-
amo et al. [5] reported dystrophic cytoskeletal changes in
olfactory epithelium of AD post-mortem tissue. Ù protein
immunoreactivity using affinity-purified antisera was de-
tected in autopsy [6] as well as in biopsy-derived olfactory
epithelium from AD patients [7]. As the latter study was
restricted to severely demented patients (Mini Mental
State, MMS [8], scores ranging from 0 to 11 of max.
30), we investigated whether specific histopathological
changes (Ù and/or ß-amyloid deposition) in the olfactory
epithelium may be detectable in AD patients with begin-
ning dementia. We therefore obtained biopsy tissue from
olfactory mucosa from 5 clinically mild to moderate AD
patients and stained for the presence of Ù or ß-amyloid by
immunocytochemistry using a panel of specific anti-
bodies.
Methods and Materials
Nasal mucosa biopsy samples were obtained from patients with
mild to moderate probable AD according to the National Institute of
Neurological and Communicative Disorders Association (NINCDS-
ADRDA) criteria [9] (n = 5, age 46–82 years, only males, MMS B SD
21 B 3, MMS range 16–24, duration of the disease: mean B SD 3.2
B 1.3 years, range 2–5 years). The Structured Interview for the Diag-
nosis of Dementia [10] score was 33 B 10 (max. 55). Two patients
were CDR stage 1 (mild dementia), 3 patients were CDR stage 2
(moderate dementia; Clinical Dementia Rating [11]). Informed con-
sent was given by each patient and their caregivers before each inves-
tigation. The biopsy patients underwent brief olfactory testing and
were able to recognize coffee, faeces, lilac, menthol, acetic acid, pyri-
dine and chloroform. The study was approved by the local ethics
committee. Autopsy samples of the olfactory mucosa from non-
demented controls of similar age (n = 5) were obtained from the Insti-
tute of Forensic Medicine, University of Munich, Germany. Brain
tissue and olfactory mucosa from 2 AD patients served as positive
controls for immunocytochemistry. Both patients were clinically
diagnosed as probable AD according to the NINCDS criteria and
were neuropathologically confirmed. The first AD case was an 88-
year-old woman. The post-mortem delay was 2 h. The patient was
clinically described as severely demented. The duration of the dis-
ease was 3 years. No familial history of dementia was reported and
the patient suffered from minor depression. Other disorders included
chronic heart failure, sick sinus syndrome, diabetes mellitus II and
polyneuropathy. The neuropathological investigation showed nu-
merous senile plaques and neurofibrillary tangles in the hippocam-
pus, parahippocampus, entorhinal cortex and cortex. The Braak [12]
staging was V. No other CNS disease was detected. Pneumonia
caused by aspiration was indicated as cause of death. Other internal
disorders included diabetic retinopathy, diabetic nephropathy and
systemic amyloidosis (liver, heart, lung). The second AD case was an
86-year-old woman. The post-mortem delay was 38 h. The patient
was clinically described as severely demented and the duration of the
disease was 7 years. No familial history of dementia was reported.
The patient suffered from chronic pain and chronic right heart fail-
ure. The neuropathological investigation showed numerous senile
plaques and NFTs in the hippocampus, parahippocampus, entorhi-
nal cortex, amygdala and cortex. The Braak staging was V. No other
CNS disease was detected. Acute right heart failure and pulmonary
embolism were documented as causes of death. Other disorders
included emphysema, pericarditis and deep-vein thrombosis (right
leg).
Biopsies of the olfactory mucosa were performed by using the
technique of Lovell et al. [13]. During local anaesthesia with 4% lido-
caine an approximately 2 mm3 small piece of tissue was removed
with a cup forceps from the superior and medial nasal turbinate using
a rhinoscope. The tissue samples were immediately placed in 4%
phosphate-buffered paraformaldehyde and fixed for 24–48 h. For
immunohistochemical experiments the samples were cut into 10-Ìm
sections with a freezing microtome. After blockage of endogenous
peroxidase, the serial sections were incubated overnight with a
monoclonal antibody (mAb) against Ù, called AT8 [14] or a polyclo-
nal antibody (pAb; Dako, Hamburg, Germany). The mAb AT8 rec-
ognizes an epitope including Ser202 when phosphorylated, the pAb
from Dako recognizes the C-terminal epitope of human Ù. Additional
antibodies used for staining included affinity-purified polyclonal
anti-ß-amyloid (ß-A4, Boehringer Mannheim) and polyclonal anti-
neuron-specific enolase (NSE, Dako) to visualize nerve fibres. All
antibodies were used in a concentration of 10 Ìg/ml in Tris-phos-
phate-buffered saline, containing 0.3% Triton X-100 and 1% normal
goat serum. Routine immunocytochemistry was performed with the
peroxidase-antiperoxidase method [15], using diaminobenzidine as
substrate for visualizing the immunoreactivity. Sections were slightly
counterstained with haematoxylin and analysed and photodocu-
mented with a Zeiss axiophot microscope.
Results
The results are summarized in figures 1–7. Brain tissue
of patients with AD shows very bright immunohisto-
chemical staining of Ù in NFTs and in nerve fibres within
neuritic plaques with each of the anti-Ù antibodies (fig. 4).
In the nasal tissue, nerve fibres were identified by positive
NSE staining (fig. 5 and 6).
In postmortem tissue from neuropathologically con-
firmed AD cases, Ù immunoreactivity was detected in fine
nerve fibres in the lamina propria and in a few olfactory
epithelial cells (fig. 1–3). Using the mAb AT8 and the pAb
from Dako gave similar results. In contrast, neither the
autopsy samples from non-demented controls nor the
biopsy specimens from probable AD patients showed any
Ù-immunoreactive neurites (fig. 7). ß-Amyloid was not
detectable in any of the tissue samples from nasal mucosa
(data not shown).
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Fig. 1. Cross-section through the nasal mucosa (autopsy tissue) of a neuropathologically confirmed AD case (stage
V-VI in Braak’s classification). Arrowheads indicate mAb AT8 Ù-immunoreactive nerve fibres in the lamina propria
and a thin fibre surrounding a subepithelial gland. Magnification: !200.
Fig. 2. Cross-section through the nasal mucosa (autopsy tissue) of a neuropathologically confirmed AD case (stage
V-VI in Braak’s classification). Arrowheads indicate mAb AT8 Ù immunoreactivity in the olfactory epithelium and
fine fibres of the lamina propria. Magnification: !500.
Fig. 3. Cross-section through the nasal mucosa (neighbouring to 1, autopsy tissue) of a neuropathologically con-
firmed AD case incubated with non-immune IgG. Note the absence of staining clearly indicating the negative control
used in these experiments. Magnification: !200.
Fig. 4. Anti-Ù AT8 immunoreactivity in frontal cortex (post-mortem tissue) of an AD case. This tissue served as
positive control and clearly showed dense staining of abnormal cytoskeletal elements in neurons and neurofibrillary
structures in a plaque (arrowheads). Magnification: !400.
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Fig. 5. NSE staining of nerve fibres in the subepithelial connec-
tive tissue of nasal mucosa. Tissue was obtained from a non-
demented control autopsy. Magnification: !500.
Fig. 6. Cross-section through the nasal mucosa obtained by biop-
sy from a patient with moderate AD. High-power magnification of
nerve fibres stained by anti-NSE pAb. Magnification: !800.
Fig. 7. Neighbouring section, depicting the same nerve fibres as
shown in figure 6, stained with anti-Ù. Note the complete absence of
immunoreactivity. The finding is representative of all tissue sections
and patients investigated. Magnification: !800.
Discussion
Histopathological changes in the olfactory epithelium
have been discussed as potential diagnostic markers of
AD. However, to date, Ù immunoreactivity has been dem-
onstrated only in autopsy material [6] or biopsy-derived
nasal mucosa from severely demented AD patients [7].
These findings were confirmed in the two late-stage AD
cases of this study, which showed severe neurofibrillary
changes throughout the limbic (i.e. entorhinal cortex) and
isocortical areas (i.e. frontoparietal, temporal cortex). In
these cases Ù immunoreactivity was demonstrated in fine
submucosal nerve fibres and in a few primary sensory
cells of the olfactory epithelium.
To serve as a tool for early diagnosis in AD, a potential
marker should be present during early progression of AD.
Although brain areas belonging to the olfactory system are
consistently affected during the neurodegenerative pro-
cess, i.e. plaques, NFTs and cell loss in the olfactory bulb,
olfactory nuclei and amygdala [16–18], it is presently
unknown at what stage during the disease pathological
neuronal changes spread to the peripheral olfactory epi-
thelium and related nerve fibres. Using a panel of highly
specific monoclonal antibodies, we were unable to detect
the presence of Ù or ß-amyloid in olfactory mucosa in any
of the 5 AD patients with beginning dementia. The
patients had been carefully diagnosed using standard clin-
ical criteria and were shown to have mild to moderate
AD. Due to the consistently negative results and because
of the invasive diagnostic procedure, the study was not
expanded beyond this point. Although the number of
patients was relatively small, the identical results in all
patients suggest that olfactory biopsies may not be useful
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as a diagnostic procedure in early AD. It is tempting to
speculate that, as Ù immunoreactivity is detectable in
patients with severe dementia [7], the occurrence of
abnormal Ù proteins in the olfactory mucosa might reflect
the progression from mild/moderate to severe stages of
the disease. In addition to the poor sensitivity of Ù staining
in the nasal mucosa of AD patients, recently, the specifici-
ty of abnormal Ù protein staining has been questioned.
Kishikawa et al. [19] described the appearance of abnor-
mal Ù proteins in the olfactory epithelium even in post-
mortem tissue from young patients without dementia.
Similar, neuritic changes in the olfactory epithelium are
also found in a number of neurodegenerative disorders
and in neurologically healthy humans [20].
In contrast to the autopsy procedures, the amount of
material obtained by biopsy is much less. However,
obtaining more material by biopsy from deeper regions of
the nose would increase the risk of side-effects, such as
bleeding or a reduction of the olfactory sensorium. There-
fore, more invasive procedures than the one described in
the present study were not performed. It can therefore not
be completely excluded that the absence of Ù-reactive neu-
rites in biopsies from living AD patients may be, at least
in part, due to limitations of the technique. Nevertheless,
it has to be emphasized that the overall goal of this study
was to contribute to the development of a clinical diagnos-
tic tool for early diagnosis of AD. Both medical and ethi-
cal concerns make it unlikely that any nasal biopsy tech-
nique more invasive than the technique applied here
would be suitable for widespread use. On the other hand,
it is unlikely that the lack of Ù immunoreactivity is due
solely to technical reasons, as the autopsy cases demon-
strated Ù immunoreactivity also in the subepithelium. As
in the biopsy cases nerve fibres were clearly demonstrated
in the subepithelium (fig. 6), one may expect Ù immunore-
activity in these samples as well. Finally, there is another
argument that supports the assumption that a milder
severity of the disease may be the major explanation for
Ù immunoreactivity lacking in nasal biopsy tissue. It has
been shown that central parts of the olfactory system are
more affected than peripheral parts (glomeruli and mitral
cells of the olfactory bulb) during neurodegeneration in
AD and that, within the olfactory system, the anterior
olfactory nucleus is predominantly involved [21]. These
findings would be consistent with the hypothesis of an
anterograde spreading of neurodegenerative changes in
the olfactory system. Therefore, the occurrence of Ù im-
munoreactivity in olfactory tissue would be expected in
more advanced stages of the disease. Another issue that
should be considered is that abnormal Ù reactivity was
demonstrated in early-stage AD patients in the entorhinal
region and olfactory nuclei [12] and that olfactory dys-
function occurs as an early sign of the disease. Since olfac-
tory neurons show a higher potential for regeneration
compared to neurons of the CNS, olfactory dysfunction
might be due to CNS neuronal degeneration in central
olfactory pathways and might not be associated with
cytoskeletal abnormalities in the olfactory neurons them-
selves. All patients were able to complete a brief olfactory
standard test. Therefore, it remains unclear whether ab-
normal Ù staining in olfactory mucosa is restricted to
patients where olfactory dysfunction can be demon-
strated.
In contrast to Ù staining in nasal mucosa, ELISA quan-
titation of Ù protein in cerebrospinal fluid (CSF) may cor-
roborate the clinical diagnosis of AD. To date, several
groups have demonstrated significantly increased CSF
levels of Ù protein in AD patients as compared to a variety
of age-matched control groups [22, and others].
However, although the staining for Ù proteins and amy-
loid deposits in nasal mucosa may not be useful for the
early diagnosis of AD, the investigation of olfactory struc-
tures may help to elucidate changes in metabolism and
signal transduction occurring in the central nervous sys-
tem of AD patients, i.e. demonstration of reduced cAMP
production in tissue cultures of olfactory epithelium [23].
In addition to the mAb AT8, several phosphorylation-
dependent Ù antibodies are available. Ù in NFTs is hyper-
phosphorylated at various sites. The use of other phos-
phorylation-dependent Ù antibodies than AT8, in nasal
mucosa, may help clarify the diagnostic properties of this
method.
In summary, the present findings support the idea that
neurodegenerative changes in the olfactory epithelium are
not primary or specific characteristics of AD. The investi-
gation of nasal mucosa biopsy samples may provide cer-
tain insights into the biochemical and morphological phe-
nomena occurring during the course of AD. It remains to
be seen whether it will provide a useful tool for the corro-
boration of the clinical diagnosis of early AD.
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